ExThera Medical Announces Creation of European Subsidiary
ExThera Medical Corporation, a developer of therapies for removing bacteria and viruses from blood, today announced the company’s plan to create ExThera Medical Europe and appointed Carla Kikken-Jussen as managing director of the new wholly-owned subsidiary.
Carla brings more than 30 years of experience in clinical research and the commercialization of new medical devices in the European market to ExThera Medical, where she will oversee the strategic direction for ExThera’s European operations.
“The establishment of our European subsidiary is an exciting milestone as we prepare for commercialization,” said Robert Ward, President and CEO of ExThera Medical. “Carla has a distinguished track record in medical device development and commercialization, including overseeing clinical research, regulatory affairs, quality assurance, and operations. As CEO of her company, Meditech, she successfully supported the rapid clinical adoption of many new medical devices. Carla’s strategic leadership will be invaluable as we continue our clinical research in Europe and build our operations and infrastructure for commercialization.”
Carla was most recently interim CEO and board chairwoman of Vimecon GmbH, which provides laser-based treatment of atrial fibrillation. In 2000, she founded MediTech Strategic Consultants in the Netherlands, a contract research organization for medical devices, and served as the company’s CEO until the company was acquired by MedPace in 2012. She has served as a board director for Shape Memory Therapeutics, Replication Medical, and as advisor to Greenhills Ventures. Carla has also been active in the EU Commission and Dutch Standardization Institute and has received several industry awards recognizing her accomplishments including the Next Women 100 Award in 2013, recognizing her as one of the 100 most influential business women in the Netherlands, and the Federation Businesswomen Award, as the best international female entrepreneur in 2010.
“Seraph holds incredible promise to transform the treatment of potentially lethal bloodstream infections,” said Kikken-Jussen. “Traditional treatments are costly and often result in poor outcomes, while contributing to drug resistance. They can also require lengthy hospital stays, and frequently fail to prevent patients from developing sepsis. I am eager to drive the completion of ongoing clinical trials in Europe and prepare for the commercialization of Seraph.”
Interim safety and performance data from the ongoing European clinical trial of the ‘Seraph® 100’ Blood Filter will be presented on March 20, 2018 at the International Symposium on Intensive Care and Emergency Medicine Congress in Brussels by Prof. Jan Kielstein of Academic Teaching Hospital in Braunschweig, Germany.
ExThera Medical is focused on developing easy-to-use devices for the rapid treatment of life-threatening/drug-resistant bloodstream infections, especially in the face of rising incidence rates and the spread of drug-resistant pathogens worldwide. The company’s Seraph ® Microbind ® Affinity Blood Filters can remove a broad range of sepsis-causing bacteria, viruses and toxins from whole blood. The technologies are currently under evaluation in a promising European clinical trial and recently designated by FDA for inclusion in their Expedited Access Pathway (EAP) program (Seraph 100). EAP designation is granted to devices that have the potential to satisfy unmet clinical needs in the prevention of fatal or debilitating diseases.
About ExThera Medical
Based in Martinez, Calif., ExThera Medical is a privately held medical device company developing innovative, single-use blood filters capable of capturing and removing a broad range of bacteria, viruses, parasites, toxins or other harmful substances from whole blood. The company develops therapeutic products to treat patients in the hospital or clinic, or on the battlefield. Led by an accomplished management team with extensive experience in blood-contacting devices and biomaterials, the company has strong patent protection and a growing body of data from independent laboratory studies, in addition to its participation in DARPA’s Dialysis-Like Therapeutics program. For more information, visit www.extheramedical.com.
Disclaimer: All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.
Caution: The Seraph® Microbind® Affinity Blood Filter is currently undergoing clinical evaluation and is not available for commercial sale.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Dataiku Raises $101 Million Series C to Transform and Democratize Enterprise AI Globally19.12.2018 15:00 | Pressemelding
Dataiku Inc., one of the world’s leading enterprise data science and machine learning platforms, today announced a $101 million Series C funding round led by ICONIQ Capital and supported by Alven Capital, Battery Ventures, Dawn Capital, and FirstMark Capital. This announcement follows the company’s $28 million Series B in September 2017 and the release of Dataiku 5 in September 2018. Since its founding in 2013, Dataiku has focused on the vision of democratized data science as the key to uninhibited possibilities instead of restricted technologies reserved for the elite few. Today, Dataiku provides a platform that enables enterprises to fundamentally transform their business - global leaders use it to build AI that optimizes marketing budget, enables maintenance services, anticipate market trends or detects fraud, and more. “We’re very excited about what this latest funding round represents - it’s a confirmation of our vision to build and deliver the missing block for the modern enterpr
Universal Laser Systems Expands Its Materials Database with AOK Technologies, Solvay and 3M Materials19.12.2018 13:05 | Pressemelding
Universal Laser Systems (ULS) announces the addition of AOK Technologies, Solvay and 3M™ materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The AOK Technologies, Solvay, and 3M materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: AOK Technologies TCK6 Thermally Conductive Insulator AOK Technologies TC1200 Thermally Conductive Insulator Solvay Udel® P-1700 Polysulfone (PSU) Solvay Ajedium™ Film Ultem® 1000-1000 Polyetherimide (PEI) 3M™ 1538L Rayon Acetate Woven Fabric Medical Tape Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advanta
Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases19.12.2018 13:01 | Pressemelding
Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181219005363/en/ Under the collaboration, Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent TGFβ1 with high affinity and specificity, inhibitors that selectively target activation of latent TGFβ1 localized to extracellular matrix, and a third TGFβ discovery program. Scholar Rock is responsible for antibody discovery and preclinical research through product candidate nomination, after which, upon exercising the option for a program, Gilead will be resp
Boeing-Leonardo Team Selects FLIR Systems EO/IR Surveillance Sensors for US Strategic Command UH-1N Replacement Contract19.12.2018 13:00 | Pressemelding
FLIR Systems, Inc. (NASDAQ: FLIR) announced today it has been selected by Boeing to provide the FLIR Star SAFIRE 380-HDc EO/IR surveillance sensor for the United States Air Force (USAF) UH-1N replacement contract. The replacement program will replace the current fleet of USAF UH-1N helicopters, which support the service’s nuclear intercontinental ballistic missile bases in Wyoming, Montana and North Dakota. The aircraft will also be used for training, test and operational support airlift missions. The initial contract award to FLIR is for the first four helicopters, with the total contract up to 84 MH-139 helicopters and valued at more than $40 million to FLIR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181219005203/en/ FLIR will provide its Star SAFIRE 380-HDc airborne surveillance camera as part of the Boeing-Leonardo UH-1N replacement contract (Photo: Business Wire) Boeing was awarded a $375.5 million firm-fixed-price
BOC Group Listed as a Representative Vendor in the 2018 Gartner Market Guide for Enterprise Business Process Analysis19.12.2018 12:00 | Pressemelding
The leading global provider of Enterprise Management Solutions, BOC Group, is pleased to share its recognition for its BPM suite ADONIS NP, in Gartner's latest Market Guide for Enterprise Business Process Analysis * . Thereby, BOC Group continues its recognition from the October 2018 Gartner Magic Quadrant and Critical Capabilities for Enterprise Architecture Tools reports for its EA suite ADOIT. Tobias Rausch, ADONIS product manager comments: “We are happy about getting recognized by Gartner, for the second time now, in their recently published Market Guide for Enterprise Business Process Analysis report. We see our placement in this year’s Market Guide as a testimony to our cutting-edge Business Process Analysis offering, and a validation that our strong focus on BPA is helping businesses in the digital transformation of their enterprise.” The Business Transformation Suite ADONIS NP is BOC Group's flagship product and Business Process Management and Analysis tool. This fully web-base
Slice Launch Studio Opens to Insurers and Tech Companies to Create Digital Insurance Products19.12.2018 12:00 | Pressemelding
Slice Labs Inc., a leading on-demand insurance cloud platform provider, announced today the opening of the Slice Launch Studio in downtown Toronto, which is designed to be an innovation hub for Slice and its partners to ideate, experiment, test and deploy new on-demand insurance products on the Slice Insurance Cloud Services (ICS) platform. Insurers and technology companies from around the world can come to the Launch Studio to collaborate on Hackathons, a key step in Slice’s approach to getting product to market quickly. Slice will also host events year-round, bringing together thought leaders from across the globe to discuss and address emerging and increasing risks. Slice is currently working with insurers in the U.S., Canada, UK and SE Asia to launch new on-demand insurance products, using a minimum viable product methodology which allows for launch in under three months. The Co-operators Group is the pilot partner for the Launch Studio, who recently launched duuo, both its new dig